Blushing And Can’t Stop? A New Way To Treat Rosacea

Blushing And Can’t Stop? A New Way To Treat Rosacea

Rosacea

With approximately 16 million Americans being affected by rosacea, striking sufferers after the age of 30 years old, it has often been thought that it only, or primarily affected Caucasians. This is true. However, and though uncommon, did you know that African Americans people are also afflicted with this chronic disorder that causes uncontrollable blushing to occur without warning, and disappears just as fast? [vc_empty_space height="5px"] What brings on bouts of persistent redness, according to survey responses received by the National Rosacea Society in 2002 is sun exposure, stress, weather, food, exercise, and/or skincare products. The tell-tale sign in a lighter-skinned rosacea sufferer is the red/flushed appearance. In deeper complexions, rosacea has more to do with how the skin feels, usually warm, and in some instances, there is visible inflammation and skin is oilier than usual. A cure for this sudden-blush syndrome, there isn’t. But there is RHOFADE™ (oxymetazoline hydrochloride) cream, 1%, a topical rosacea treatment that can only be acquired with a doctor’s prescription.

How does Rhofade work?

RHOFADE™ is an alpha1A adrenoceptor agonist that acts as a vasoconstrictor and is approved for the topical treatment of persistent facial erythema associated with rosacea in adults. Been down this road before and still nothing has worked? To help inform your decision, see the results of two Rhofade clinical trials below with a once-daily application. When two users used RHOFADE over the course of 29 days, it was proven to reduce persistent facial erythema associated with rosacea through 12 hours. [fullwidthimage photourl="https://www.hueknewit.com/wp-content/uploads/2017/10/rhofade-clinical-results.jpg"] Clinical Trial Details: The primary efficacy endpoint was at day 29 and defined as the proportion of patients with at least a 2-grade reduction in erythema (improvement) from baseline (pre-dose on day 1) on both the clinician erythema assessment (CEA) and subject self-assessment (SSA) (composite success) measured at hours 3, 6, 9 and 12 versus vehicle. CEA and SSA also measured at Days 1 and 15 at hours 3, 6, 9, and 12.

Side Effects

Common side-effects include application-site skin reactions (dermatitis), worsening of rosacea pimples, itching, redness, and pain. If after using Rhofade you experience a side-effect other than what’s been listed, you are encouraged to report it to the FDA or contact 1-800-FDA-1088. For more product information click here.

Leave a comment

Your email address will not be published. Required fields are marked *

Please note, comments must be approved before they are published